Core Viewpoint - The announcement details the completion of the China Securities Regulatory Commission (CSRC) filing for the conversion of certain unlisted shares of Fosun Pharma's subsidiary, Fuhong Hanlin, into H-shares for listing on the Hong Kong Stock Exchange [2][3]. Group 1: Filing Situation - Fuhong Hanlin has received a filing notice from the CSRC regarding the conversion of a total of 182,645,856 shares held by several shareholders into H-shares, including 120,000,000 shares held by Fosun Pharma's subsidiary, Fosun New Drug [3]. Group 2: Impact on the Listed Company - As of the announcement date, the company holds a total of 344,730,800 shares in Fuhong Hanlin, representing approximately 63.43% of its total share capital. The conversion of the 120,000,000 unlisted shares into H-shares will not change the total number of shares held by the company, which will remain at 152,331,100 H-shares and 192,399,700 unlisted shares [4]. - The company has no plans to reduce its holdings in Fuhong Hanlin, reflecting confidence in the development and value of Fuhong Hanlin and its subsidiaries [2][4].